Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
about
Autonomic Dysregulation in Multiple SclerosisOrthostatic Hypotension: Mechanisms, Causes, ManagementCurrent pharmacological management of hypotensive syndromes in the elderly.Diagnosing and treating neurogenic orthostatic hypotension in primary care.Neurogenic orthostatic hypotension - management update and role of droxidopaDroxidopa in neurogenic orthostatic hypotension.Validation of a questionnaire for orthostatic hypotension for routine clinical use.Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease.Orthostatic hypotension: pathophysiology, assessment, treatment and the paradox of supine hypertension.The Treatment of Primary Orthostatic Hypotension.Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopaTherapeutic advances in multiple system atrophy and progressive supranuclear palsy.Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.Orthostatic hypotension: managing a difficult problem.Implications of Recent Drug Approvals for Older AdultsDroxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic HypotensionThe role of deep brain stimulation in Parkinson's disease: an overview and update on new developments.Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.Progress in the treatment of small fiber peripheral neuropathy.Recent advances in orthostatic hypotension presenting orthostatic dizziness or vertigo.New clinical trials for nonmotor manifestations of Parkinson's disease.Recognition and treatment of autonomic disturbances in Parkinson's disease.Therapeutic approaches in Parkinson's disease and related disorders.Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies.New and emerging medical therapies in Parkinson's disease.Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.Nondopaminergic treatments for Parkinson's disease: current and future prospects.New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study.The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.Multiple system atrophy: insights into a rare and debilitating movement disorder.Multiple System Atrophy - State of the Art.Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension.Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms.Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.
P2860
Q26799341-9AA916E7-101D-4922-BC2F-6AD6E6AC31C8Q26801811-5F7AD94F-8C22-425A-BD98-9E4CCE3FCC6EQ33165704-169193F8-ADDA-41E6-863D-CCD148154F85Q33165773-501FCA76-3ECE-43CD-9773-291F9B328690Q33165870-F8F7B000-6FB0-4118-8AB2-0F969E3E3B97Q33165878-D96347F8-7917-4546-A3D0-4F327159C5D9Q33166010-50B67890-0B14-4011-9C24-29913F100C74Q33166368-4F8CF91A-576E-4D41-95FD-A20F85BA377EQ33167390-DF20913D-FF3B-4167-99FB-DF6185D82387Q33168147-F3CE695F-69D6-42DD-B380-9713D4DF8B06Q33667809-106D4AC0-8181-4C4C-94A1-B56919254171Q34445249-051AAE75-DD0C-4D29-8674-6CE2828B3010Q34487619-4B74838D-4E23-4259-88A8-727C8E72C1A1Q35417194-B800720C-DEBD-4508-B7DF-B22B80C26FD9Q35671396-E6E988F7-8B8A-4954-8672-086EFE70545CQ36107373-3818E552-D985-4067-B053-B4ADCAC6A1FDQ36943826-D0B5F336-5961-4E4E-BE60-BF1FFB56230DQ37025152-A72432E5-D0E1-4610-B475-42C9AC464AFFQ37265850-B84FCB64-8F23-41D8-93F1-D28CE225D64AQ37698671-FB50D1BA-53B9-4E97-AFEB-9DDC5750D593Q38258228-6AD2479D-7C3C-44EF-BBF6-2AEE07DCB56DQ38307583-DC06C481-D2A6-4CC6-BBDA-3C735058A683Q38349089-4CF984F1-1906-4E32-855A-B976ADD543C8Q38570377-A9ABE642-16E7-4A84-94BF-5C922B504753Q38587090-0DDA440C-2A3B-45B6-941B-D458BBDAE291Q38594855-A0897FB8-3CF7-4B76-BB11-DA5C3807429AQ38691406-7B74F3E3-92F3-477D-80C9-F8F25C34321AQ38712697-792513DE-7837-44B7-B528-AF897599175AQ38718194-5DDF7113-0A91-4DC8-9C6A-778D2127D04CQ38764011-79D87709-6E35-49DC-8BD4-E507464FBD6CQ38845546-2EECB2E8-0984-4D6D-802C-A15F95D789BFQ39006423-2A26C2A4-AC70-4225-B9A9-C2F57C8D7857Q39052115-AB0F846B-8B94-4128-8CCF-A8CB974F0D70Q39066747-0B166638-547C-41A5-911C-B0C35703E3A4Q39183459-86F27F53-89AF-4F17-8DE5-8E02FB864EC9Q39220912-ABF69F51-31F4-486B-841B-59085E28D6BDQ39438327-16675C93-01F1-44C5-A6B1-5F76BC9CEEC0Q40495838-933EF837-379A-40B8-8610-7D4AF2E96A01Q44746489-9C3A03D7-85B3-4082-8C22-BA03C966BA97Q47651254-F88AD2A1-DC61-49E3-83F0-D7E011273D6A
P2860
Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.
@ast
Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.
@en
type
label
Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.
@ast
Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.
@en
prefLabel
Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.
@ast
Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.
@en
P2093
P2860
P921
P1433
P1476
Droxidopa for neurogenic ortho ...... ebo-controlled, phase 3 trial.
@en
P2093
Christopher J Mathias
Italo Biaggioni
Joe Mauney
L Arthur Hewitt
Michael Feirtag
NOH301 Investigators
Phillip Low
Roy Freeman
Simon Pedder
P2860
P304
P356
10.1212/WNL.0000000000000615
P407
P577
2014-06-18T00:00:00Z